Inventor · disambiguated record
Kristel Kemper
Also filed as: KEMPER KRISTEL
5 granted patents·7 pending applications·3 citations·filing 2020–2025
70Inventor score
Files withGENMAB AS12
Top patents by PatentIndex Score
12 records- 0191US11008399B2AntibodiesGENMAB AS·Filed 2020·Granted May 18, 2021·2 cites·22 claims
- 0288US11130819B2AntibodiesGENMAB AS·Filed 2021·Granted Sep 28, 2021·1 cites·30 claims
- 0385US2024392032A1AntibodiesGENMAB AS·Filed 2024·Application pending·0 cites
- 0479US12410258B2Antibodies capable of binding to OX40, variants thereof and uses thereofGENMAB AS·Filed 2024·Granted Sep 9, 2025·0 cites·23 claims
- 0576US11970544B2AntibodiesGENMAB AS·Filed 2021·Granted Apr 30, 2024·0 cites·31 claims
- 0671US11814437B2Antibodies binding to CD30 and CD3GENMAB AS·Filed 2022·Granted Nov 14, 2023·0 cites·16 claims
- 0769US2024228641A9Antibodies binding to cd30 and cd3GENMAB AS·Filed 2023·Application pending·0 cites
- 0868US2020277397A1AntibodiesGENMAB AS·Filed 2020·Application pending·0 cites
- 0963US2025333526A1Antibodies capable of binding to ox40, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 1063US2025333527A1Antibodies capable of binding to ox40, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 1151US2023310599A1Antibody therapyGENMAB AS·Filed 2021·Application pending·0 cites
- 1250US2023257479A1Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancerGENMAB AS·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →